eGFR 43 Meaning: What It Says About Kidney Health

Uncover what an eGFR of 43 reveals about your kidney health. Gain clarity on its significance and navigate the path toward informed care.

An eGFR of 43 means your kidneys are filtering blood at roughly 43 percent of what a healthy young adult’s kidneys would manage, placing you in Stage 3b chronic kidney disease (CKD). That stage sits in a clinically meaningful zone: not yet severe enough for dialysis conversations, but low enough that kidney-protective treatment and close monitoring become genuinely important. The number itself, though, is just a snapshot, and understanding what drives it, what threatens to push it lower, and what can stabilize it matters far more than the number alone.

What the Number Actually Represents

eGFR stands for estimated glomerular filtration rate. It approximates how many milliliters of blood your kidneys’ tiny filtering units, called glomeruli, clean per minute. The “e” is important: it’s an estimate, not a direct measurement. Most labs calculate it from a blood test for creatinine, a waste product your muscles produce at a fairly steady rate. The most widely used formula today is the CKD-EPI 2021 equation, which factors in your creatinine level, age, and sex to spit out a single number.

A normal eGFR is above 90. CKD staging breaks the range below 60 into bands: Stage 3a runs from 45 to 59, Stage 3b from 30 to 44, Stage 4 from 15 to 29, and Stage 5 is below 15, which is when kidney failure and dialysis enter the picture. At 43, you’re right at the top of Stage 3b. That placement is not arbitrary: research shows that people in this range face meaningfully higher risks of progression, hospitalization, and cardiovascular events than those even a few points higher in Stage 3a.

How Reliable Is That 43?

Creatinine-based eGFR has blind spots. Your muscle mass, diet, hydration level, and even a steak dinner the night before can nudge creatinine up or down independently of how your kidneys are actually performing. A very muscular person may get a falsely low eGFR, while someone with little muscle mass, such as an older adult who is frail, may get a falsely reassuring number. This is one reason nephrologists sometimes order a second marker called cystatin C, a small protein filtered by the kidneys that is less sensitive to muscle mass. In general-population studies, cystatin C-based eGFR reclassified a meaningful share of people into different risk categories compared to creatinine alone, and those reclassifications predicted real differences in outcomes like death and cardiovascular events.

Beyond the choice of blood marker, the formulas themselves carry inherent imprecision. Different equations can give different eGFR values from the same blood sample, and accuracy tends to be worst at higher filtration rates. For someone hovering around 43, the estimates are generally more reliable than they are at, say, 90, but a single reading can still fluctuate by several points depending on the day. If your eGFR result seems inconsistent with how you feel or with other test results, your doctor may repeat the test or order cystatin C to get a clearer picture.

The Race Coefficient and Why It Changed

Until 2021, the most common eGFR equations included a “race coefficient” that automatically reported higher values for Black patients. The rationale was based on population-level differences in average creatinine, but the practice was increasingly recognized as harmful. The older formulas placed some Black patients in less severe CKD stages than their actual kidney function warranted, potentially delaying referrals to nephrology, transplant evaluation, and access to Medicare coverage for kidney disease. The CKD-EPI 2021 equation removed race from the formula entirely. If your eGFR of 43 was calculated using this updated equation, it is race-neutral. If you have old lab results that used the previous formula, your current and past numbers may not be directly comparable, and it’s worth asking your doctor which version was used.

What Usually Causes Kidneys to Reach This Level

The two most common culprits behind a declining eGFR are diabetes and high blood pressure, often acting together. In people with reduced kidney function, elevated blood sugar and elevated blood pressure are present in the vast majority of cases. Diabetes damages the small blood vessels in the kidneys’ filtering units over years, while high blood pressure pushes blood through those filters at excessive force, accelerating scarring. Hypertension drives eGFR decline partly through higher pressure inside the glomeruli themselves and progressive hardening of the kidney’s arteries.

Other conditions that can land someone at an eGFR of 43 include autoimmune diseases like lupus, inherited conditions like polycystic kidney disease, recurrent kidney infections, obstruction from kidney stones or an enlarged prostate, and long-term use of certain medications. In people with type 2 diabetes specifically, the list of factors linked to faster kidney decline is long: smoking, obesity, anemia, vitamin D deficiency, poorly controlled blood sugar, and high blood pressure all contribute.

Why Kidney Damage Tends to Snowball

One frustrating feature of kidney disease is that damage begets more damage. When some filtering units are destroyed, the surviving ones compensate by working harder, filtering more blood per unit than they were designed to handle. This compensatory hyperfiltration keeps your overall eGFR from crashing immediately, but it stresses each remaining nephron and makes them more vulnerable to further injury. Over time, that overwork drives scarring and inflammation in the kidney tissue, leading to fibrosis that destroys still more nephrons.

Animal research has shown this cycle in stark detail. After a large portion of kidney mass is removed, the remaining kidney initially recovers much of its filtering capacity through hyperfiltration, but within weeks to months fibrosis sets in and GFR starts dropping again. This self-reinforcing loop is a major reason why early intervention at Stage 3b matters so much: the goal is to reduce the strain on surviving nephrons before the fibrosis cycle becomes too entrenched to slow down.

Progression Risk at eGFR 43

Not everyone with an eGFR of 43 will progress to kidney failure. A retrospective study of patients whose average baseline eGFR was 43 found that over a median follow-up of about two and a half years, roughly one in five progressed to Stage 4 CKD, about 3 percent reached end-stage kidney disease, and about 12 percent died. Around 43 percent were hospitalized for any reason during that period. Those numbers capture average risk across a mixed population; your individual trajectory depends heavily on what caused the kidney decline, how well risk factors are managed, and whether you experience acute kidney injuries along the way.

Acute kidney injury, where kidney function drops sharply over hours to days due to dehydration, infection, surgery, or a nephrotoxic medication, is itself a significant risk factor for long-term non-recovery. People who already have reduced kidney function going into an acute episode are less likely to bounce back fully. This is a practical reason why people with an eGFR of 43 are advised to stay well hydrated during illness, to avoid certain over-the-counter painkillers, and to flag their kidney status before any procedure that involves contrast dye or general anesthesia.

The Heart-Kidney Connection

Heart disease is actually a bigger immediate threat than kidney failure for most people at Stage 3b. Reduced kidney function creates a chronic inflammatory state that accelerates damage to blood vessels and the heart. The kidneys and cardiovascular system are tightly linked: when kidneys falter, stress hormones and inflammatory signals ramp up, calcium deposits form in artery walls, and the heart muscle itself can begin to stiffen and remodel. Researchers have described CKD as mimicking accelerated aging of the cardiovascular system, and this effect is already significant even in the earlier stages of kidney disease, though it intensifies considerably in Stages 4 and 5.

Part of this cardiovascular toll comes from specific biochemical shifts. The kidneys normally produce an enzyme that helps break down stress hormones called catecholamines. As kidney function drops, this enzyme’s activity falls, leaving the sympathetic nervous system in a state of chronic overdrive that promotes high blood pressure and vessel damage. Managing blood pressure aggressively, keeping cholesterol in check, and not smoking are all more important at an eGFR of 43 than in someone with normal kidney function, precisely because the baseline cardiovascular risk is already elevated.

Medications That Can Slow Progression

SGLT2 inhibitors, a class of drugs originally developed for type 2 diabetes, have become a cornerstone of kidney protection regardless of whether diabetes is present. These medications work by reducing the pressure inside the kidney’s filtering units, easing the hyperfiltration burden on remaining nephrons. A meta-analysis found that SGLT2 inhibitors slowed the annual rate of eGFR decline, cut the risk of reaching end-stage kidney disease by about 30 percent, and reduced albuminuria by roughly 37 percent. Even in people with advanced CKD and type 2 diabetes, SGLT2 inhibitor use was associated with a substantially lower rate of new-onset kidney failure compared to controls.

ACE inhibitors and ARBs, medications that lower blood pressure by blocking the renin-angiotensin system, remain important as well. They reduce pressure inside the glomeruli and decrease protein leakage into the urine, which itself is a driver of kidney scarring. For many people at Stage 3b, the combination of an ACE inhibitor or ARB with an SGLT2 inhibitor, along with good blood pressure and blood sugar control, represents the current best-practice strategy to slow progression.

Medication Dosing Changes at This Level

An eGFR of 43 affects more than just kidney-specific drugs. Many common medications are cleared through the kidneys, and at this filtration rate, doses often need to be adjusted to avoid toxicity. The CKD-EPI equation is recommended as the primary tool for estimating kidney function when making these adjustments, though clinicians also consider the specific drug’s properties and the patient’s overall clinical picture.

Some practical examples: metformin, widely used for diabetes, was once contraindicated below an eGFR of 60 but is now generally considered safe down to 30 with dose reduction. Certain antibiotics, gout medications, and some blood pressure drugs require lower doses. Over-the-counter anti-inflammatory drugs like ibuprofen and naproxen can further reduce kidney blood flow and should generally be avoided or used only briefly and with medical oversight. If you’re at an eGFR of 43, keeping an updated medication list and making sure every prescriber knows your kidney status is one of the single most protective things you can do.

Is It Age or Disease?

Kidney function declines naturally with age, which creates a real diagnostic gray area in older adults. A systematic review of the rate of kidney function decline with age found meaningful variability from person to person, but the general trend is downward. The current definition of CKD uses a fixed cutoff of eGFR below 60 regardless of age, which has prompted debate in the nephrology community. Some researchers have argued that in older adults with eGFR values between 45 and 59 and no protein in the urine, the reduced number may reflect normal kidney aging rather than a disease process that threatens their health.

At 43, though, you’ve crossed below the range where this debate is most active. An eGFR of 43 in a 40-year-old is unambiguously abnormal. In an 85-year-old with no protein in the urine and stable numbers over years, the clinical picture is less alarming, but it still warrants monitoring for further decline. The context around the number, specifically whether there is albuminuria, how fast eGFR has been falling, and what other health conditions are present, matters as much as the number itself.

Diet and Lifestyle at Stage 3b

Dietary changes at this stage are not about curing the disease; they’re about reducing the workload on your kidneys and preventing complications. Protein restriction has long been a pillar of CKD nutrition advice, with the logic that less protein means fewer waste products for the kidneys to clear. International guidelines generally recommend limiting protein intake in CKD, though the evidence for a specific threshold is less ironclad than you might expect. In practice, most nephrologists advise moderate protein intake rather than aggressive restriction at Stage 3b.

Salt restriction is arguably equally important. Excess sodium drives fluid retention, raises blood pressure, and increases the protein leaking through your kidney filters, all of which accelerate kidney decline. Research in CKD patients using a combined low-protein, low-salt dietary approach found average sodium intake could be brought down to manageable levels with meaningful reductions in circulating toxins that damaged kidneys struggle to clear. Beyond protein and salt, potassium and phosphorus management become increasingly relevant as eGFR drops further. At 43, your doctor may not yet restrict these aggressively, but lab values for both should be tracked.

Acid Buildup and Bone Health

A less visible consequence of an eGFR in the low 40s is the kidney’s diminishing ability to handle the body’s acid load. Healthy kidneys excrete acid and regenerate bicarbonate to keep blood pH stable. As filtration drops, acid can accumulate even before blood tests show overtly abnormal numbers, a condition sometimes called subclinical metabolic acidosis. Research has shown that treating this acid buildup with oral sodium bicarbonate can slow eGFR decline even in patients whose blood bicarbonate levels still look normal.

Acid accumulation also has downstream effects on bones and muscles. The body buffers excess acid partly by pulling calcium and other minerals from bone, which over time contributes to the bone disease commonly seen in advanced CKD. At an eGFR of 43 you may not yet have obvious bone symptoms, but your doctor should be monitoring calcium, phosphorus, parathyroid hormone, and vitamin D levels. Catching and treating mineral imbalances early can prevent a cascade of complications later.

Monitoring and When to See a Nephrologist

Guidelines from major kidney disease organizations generally recommend referral to a nephrologist at Stage 3b or when there is significant protein in the urine. In practice, referral rates are lower than they should be. A large registry study found that even among patients who met formal criteria for nephrology referral, only about 20 to 37 percent actually saw a nephrologist within a year, depending on how much protein was in their urine. If your eGFR is 43 and you haven’t been referred, it’s reasonable to ask for one yourself.

Routine monitoring typically includes eGFR and creatinine every three to six months, urine albumin-to-creatinine ratio to track protein leakage, blood pressure at every visit, and periodic checks of potassium, phosphorus, bicarbonate, hemoglobin, and parathyroid hormone. The trend in your eGFR over time is more informative than any single reading. A slow, stable decline of roughly one point per year is common with aging; a drop of more than three to five points per year suggests something more aggressive is happening and warrants investigation.

The Emotional Side of Seeing That Number

Getting told your kidneys are working at less than half capacity can be jarring. In surveys of people newly diagnosed with CKD, the most common emotional responses were worry and fear, reported by about 28 percent of respondents, followed closely by shock at around 25 percent. A notable share, about 27 percent, reported no strong reaction at all, often because the condition wasn’t affecting their daily life in any noticeable way. Over time, the psychological burden tends to grow with disease severity. Across all stages, about 38 percent of CKD patients reported anxiety, depression, or sleep disturbance as significant impacts on their lives.

Patients frequently described feeling confused by the diagnostic process and poorly informed about what their numbers meant, which amplified their anxiety. A separate study of a CKD cohort found that how people perceived their illness, whether they saw it as controllable or overwhelming, significantly influenced their levels of depression and anxiety, with maladaptive coping strategies making the emotional toll worse. If an eGFR of 43 is making you anxious, that reaction is common and understandable, and it’s worth bringing up with your care team. Feeling informed and having a clear management plan tends to make the diagnosis feel less threatening than a number delivered without context.